Clinical Trial Update: Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib in combination with TAS-102 for advanced pancreatic cancer in third-line and beyond has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Surufatinib (Surufatinib)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Pancreatic Neoplasms | Phase 2 | Status: COMPLETED